Bristol-Myers Squibb Co. Third Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, October 27, 2011. Bristol-Myers Squibb is a global company that develops, manufactures, and sells pharmaceutical products.

Bristol-Myers Squibb Co. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 58 cents per share, a decline of 1.7% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 55 cents. Between one and three months ago, the average estimate moved up. It has risen from 57 cents during the last month. For the year, analysts are projecting net income of $2.28 per share, a rise of 5.6% from last year.

Past Earnings Performance: The company is looking to make a streak of three quarters of beating estimates. Last quarter, it beat expectations by reporting profit of 56 cents per share, and the previous quarter, it had net income of 58 cents.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 10.4% in revenue from the year-earlier quarter to $5.3 billion.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, one rating it as a sell and nine rating it as a hold.

A Look Back: In the second quarter, profit fell 2.7% to $902 million (52 cents a share) from $927 million (53 cents a share) the year earlier, but exceeded analyst expectations. Revenue rose 14% to $5.43 billion from $4.77 billion.

Key Stats:

Revenue has gone up for three straight quarters. It rose 4.2% in the first quarter from the year earlier and 74.9% in the fourth quarter of the last fiscal year.

The decrease in profit in the second quarter came after net income rose in the previous quarter. In the first quarter, net income rose 32.7%.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), and AstraZeneca plc (NYSE:AZN).

Stock Price Performance: During August 25, 2011 to October 21, 2011, the stock price had risen $4.37 (15.5%) from $28.19 to $32.56. The stock price saw one of its best stretches over the last year between September 9, 2011 and September 20, 2011 when shares rose for eight-straight days, rising 8% (+$2.30) over that span. It saw one of its worst periods between January 3, 2011 and January 11, 2011 when shares fell for seven-straight days, falling 2.4% (-62 cents) over that span. Shares are up $7.29 (+28.8%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.